Article
VHL Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma.
Cancer discovery - 1 Nov 2017
Yao Xiaosai, Tan Jing, Lim Kevin Junliang, Koh Joanna, Ooi Wen Fong, Li Zhimei, Huang Dachuan, Xing Manjie, Chan Yang Sun, Qu James Zhengzhong, Tay Su Ting, Wijaya Giovani, Lam Yue Ning, Hong Jing Han, Lee-Lim Ai Ping, Guan Peiyong, Ng Michelle Shu Wen, He Cassandra Zhengxuan, Lin Joyce Suling, Nandi Tannistha, Qamra Aditi, Xu Chang, Myint Swe Swe, Davies James O J, Goh Jian Yuan, Loh Gary, Tan Bryan C, Rozen Steven G, Yu Qiang, Tan Iain Bee Huat, Cheng Christopher Wai Sam, Li Shang, Chang Kenneth Tou En, Tan Puay Hoon, Silver David Lawrence, Lezhava Alexander, Steger Gertrud, Hughes Jim R, Teh Bin Tean, Tan Patrick
Abstract excerpt
Protein-coding mutations in clear cell renal cell carcinoma (ccRCC) have been extensively characterized, frequently involving inactivation of the von Hippel-Lindau (VHL) tumor suppressor. Roles for noncoding cis-regulatory aberrations in ccRCC tumorigenesis, however, remain unclear. Analyzing 10 primary tumor/normal pairs and 9 cell lines across 79 chromatin profiles, we observed pervasive enhancer malfunction in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
